Making it possible through our patient and user-centric focus.

We believe that dedication to our end users, both patients and clinicians, is the key to developing lasting technological and workflow improvements to healthcare. We strive for simplicity, robustness, and intuitiveness as foundational elements of all our imaging solutions in order to delight all who touch our technology.

1963

Baule and McFee made history when they recorded the biomagnetic signature of the heart.

This showed previously unseen and information-rich cardiac activity in a subject without any contact or energization required—a feat previously reserved for Science Fiction TV and Movies. The discovery was one of many brand-new clinical insights using the body's own energy as an indicator of health. Baule and McFee's novel insights blossomed into the field of biomagnetism.

💡 Baule & McFee's Work

2004

The United States Food and Drug Administration (FDA) authorized marketing of the first commercial MCG system utilizing SQUID technology in the United States.

Magnetocardiography’s technical and clinical development has been primarily driven by Superconducting Quantum Interference Devices (SQUID). MCG hardware has evolved steadily from single channel laboratory-based investigational devices, to high-density commercially available units.

2013

Genetesis was founded with the goal of catalyzing this science from the lab to enrich patient care.

Through always focusing on our end users and constantly scanning disciplines across science and technology, we are delivering powerful new tools to clinicians.

🎤 Watch Peeyush's Ohio State TedTalk

2019

This technological and clinical developmental process culminated in 2019 with the world’s first regulatory authorization [4]of an OPM-based MCG system for commercial sale: enter CardioFlux.

‍Genetesis receives FDA 510(k) clearance for its cardiac imaging platform. The platform pairs the CardioFlux™ Magnetocardiograph with the integrated Faraday Analytical Cloud™ (FAC).

✅ Genetesis' CardioFlux Receives FDA 510(k) Clearance

2020

The ACCMED study begins enrollment across multiple Emergency Departments in the United States as one of the largest MCG studies to ever be performed.

Device is evaluated in a pilot clinical protocol studying the value of magnetocardiography in chest pain triage.

✅ View the ACCMED trial.

The values that
shape our team's work.

If you join the team, you’ll hear over and over how we operate from “first principles”. These values are what that really means.

Collaboration
Few problems in healthcare exist in a vacuum and even fewer still stand to be solved by a single individual. Building this company and its products will require overcoming seemingly impossible problems - problems we will overcome by relying on each other's individual strengths to generate joint success.
Transparency
Success will require building trust with physicians who in turn are trusted by their very own patients. More than anything, trust is driven by boundless transparency. Inside Genetesis, a transparent culture means you'll always understand the context of your individual progress within the company's overall vision.
Empowerment
Executing our vision of empowering physicians and patients with the diagnostic certainty they need involves being empowered ourselves to be our best today... and even better tomorrow. Here, there's no such thing as a voice too small or idea too large. Voices are not just heard - they're listened to - and ideas are not just shared - they're acted upon.
Passion
Being able to work on a product that is going to materially impact people's lives - that's unbeatable. That's why, almost out of necessity, we want to work with others who are just as passionate as ourselves. After all, isn't it the passionate people who always end up pushing the boundaries of what's possible?

Our Founders

Meet the three founders who first saw the potential for MCG to change how patients experience cardiac care.

Peeyush Shrivastava

Co-Founder & CEO

Peeyush has 8 years of experience as a serial medical technology entrepreneur and technologist. He currently serves as the Co-Founder and Chief Executive Officer of Genetesis, where he has raised over $25 million in venture capital financing and led the company...

Read More →

Vineet Erasala

Co-Founder & COO

Vineet is a proven product focused executive, specializing in full lifecycle medical device development and commercial access. As Co-Founder and Chief Operations Officer of Genetesis, he is highly adept at technical and corporate strategy implementation...

Read More →

Manny Setegn

Co-Founder & CTO

Emmanuel is a highly technical co-founder and technical strategist with having had a background in software development and IT operation for nearly 10 years.  He currently serves as the Co-founder and Chief Technology Officer of Genetesis, where he has been responsible...

Read More →

"We have made it our mission to to deliver the world’s most cost-effective and patient-centric solution for cardiovascular disease."

Peeyush Shrivastava

Co-Founder and CEO of Genetesis